MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.
The conference presentation schedule is as follows: | ||
Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference | ||
December 8, 2010 at 12:30 p.m. PT | ||
Nikko Hotel, San Francisco, CA | ||
Presenter: Charles Bowden, MD, director of clinical development | ||
2010 Deutsche Bank BioFEST Conference | ||
December 14, 2010 at 4:05 p.m. ET | ||
Four Seasons Hotel, Boston, MA | ||
Presenter: Timothy Morris, chief financial officer | ||
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: | |||
VIVUS, Inc. | Investor Relations: | The Trout Group | |
Timothy E. Morris | Brian Korb | ||
Chief Financial Officer | bkorb@troutgroup.com | ||
650-934-5200 | 646-378-2923 | ||
SOURCE VIVUS, Inc.
